Precision BioSciences closes second deal for leading CAR T candidate
Durham-based gene editing company Precision BioSciences has cut a second deal in six months involving its leading off-the-shelf CAR T candidate, Azercabtagene Zapreleucel (azer-cel). Precision said it has reached an agreement with TG Therapeutics to …